指南与共识性腺与生殖内分泌垂体与肾上腺疾病

中枢性性早熟:内分泌学会临床实践指南

Central precocious puberty: an Endocrine Society clinical practice guideline.
指南 / 共识 · J Clin Endocrinol Metab · 2026-01-01

该指南由多学科专家组采用GRADE方法,针对中枢性性早熟(CPP)诊断与治疗的10个临床问题提出循证推荐。推荐包括对7.0至8.0岁乳房发育女孩先观察、以超敏基础LH起始评估、特定年龄段不常规行头颅MRI、不常规加用生长激素及不常规生化监测等。

要点

  • 7.0至8.0岁乳房发育女孩建议每4-6个月体检观察,而非立即实验室或影像评估。
  • 7岁前乳房发育女孩应先观察4-6个月以区分缓慢进展与快速进展青春期。
  • 6.0至8.0岁女孩及8.0至9.0岁男孩无中枢神经系统症状时不常规行头颅MRI。

核心结论

  • 指南针对CPP诊断与治疗中的关键不确定性提出循证推荐,旨在提供净临床获益并兼顾成本与可行性。
  • 专家组指出当前证据存在重要知识缺口,需进一步研究。

研究设计与样本

  • 多学科临床专家组联合指南方法与系统综述专家,采用GRADE方法回答10个CPP诊断与治疗临床问题。
  • 每个临床问题均进行健康获益与危害的系统综述,并使用GRADE证据到决策框架评估价值观、成本、可行性等。

主要发现

  • 7.0至8.0岁乳房发育(Tanner B2)女孩建议定期体检观察而非立即实验室或影像评估。
  • 7岁前乳房发育女孩应先观察4至6个月以区分未持续或缓慢进展与快速进展青春期。
  • 缓慢进展青春期女孩未经治疗可达正常成年身高,是上述推荐的主要证据基础。

关键数值与推荐

  • 7.0至8.0岁乳房发育女孩建议每4-6个月体检观察。
  • 7岁前乳房发育女孩先观察4至6个月。
  • 确认中枢性激活时建议以超敏基础LH起始评估而非对所有患者常规行GnRH/GnRHa激发试验。
  • 6.0至8.0岁女孩及8.0至9.0岁男孩无中枢神经系统症状时不常规行头颅MRI。
  • 不常规进行基因检测,但家族性CPP可经共享决策考虑MKRN3测序。

临床怎么用

  • 对7岁前及7.0至8.0岁乳房发育女孩先观察4-6个月再决定是否评估。
  • 以超敏基础LH起始激素评估,特定年龄段无神经系统症状者不常规行头颅MRI。
  • GnRHa治疗应起始即选用预计长期使用的剂型,不常规加用生长激素。
  • 不常规生化监测青春期抑制,仅在临床怀疑治疗失败时检测。
  • GnRHa不常规持续超过女孩10.0至11.0岁或男孩11.0至12.0岁,或相应骨龄上限。

局限性

  • 部分推荐基于缓慢进展青春期女孩未经治疗可达正常成年身高的证据,适用范围有限。
  • 专家组指出指南制定过程凸显重要知识缺口,需大量额外研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Central precocious puberty (CPP), which is traditionally defined as the development of secondary sexual characteristics before age 8 years in girls and age 9 years in boys, results from the premature activation of the hypothalamic-pituitary-gonadal (HPG) axis. CPP can be associated with short adult stature, adverse psychosocial outcomes, and increased cardiometabolic and cancer risks in adulthood. Gonadotropin-releasing hormone (GnRH) agonists can effectively suppress premature activation of the HPG axis and have the potential to increase adult height as well as improve psychosocial and long-term health outcomes among patients with CPP. However, as secular trends have continued to shift toward earlier age of pubertal onset, some subpopulations of children with CPP, as it is currently defined, may not require the same extent of diagnostic evaluation and treatment. OBJECTIVE: Develop evidence-based recommendations related to the diagnosis and treatment of CPP. METHODS: A multidisciplinary panel of clinical experts, along with experts in guideline methodology and systematic literature review, used the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach to address 10 clinical questions related to the diagnosis and treatment of CPP. Systematic reviews of health-related benefits and harms were conducted for each clinical question. The guideline development panel (GDP) also used the GRADE evidence-to-decision (EtD) framework to address stakeholder values and preferences, costs and required resources, cost-effectiveness, acceptability, feasibility, and potential impacts on health equity. RESULTS: In girls with thelarche (Tanner stage B2) between ages 7.0 and 8.0 years, the GDP suggests watchful waiting via periodic physical examinations (every 4-6 months) rather than immediately performing evaluation with laboratory testing or radiologic imaging. In addition, the GDP suggests that all girls with breast development (ie, Tanner stage B2) before age 7 years should first be observed for 4 to 6 months to differentiate unsustained or slowly progressive puberty vs rapidly progressive puberty. These recommendations are largely based on evidence that girls with slowly progressive puberty attain a normal adult height without treatment. When hormonal evaluation is performed to confirm central (GnRH-dependent) activation as the cause of precocious puberty, the GDP suggests starting the evaluation with ultrasensitive basal luteinizing hormone (LH) concentration rather than routine GnRH/GnRH agonist (GnRHa) stimulation testing for all patients. While brain magnetic resonance imaging has been a traditional part of CPP evaluation, the GDP suggests that it should not be routinely performed in girls ages 6.0 to 8.0 years and boys ages 8.0 to 9.0 years without central nervous system (eg, neuro-ophthalmologic) symptoms, largely based on a low prevalence of pathologic intracranial findings in these age groups. The GDP suggests against routine genetic testing for patients with CPP, although they judged that genetic testing (eg, MKRN3 sequencing) should be considered for patients with familial CPP through a shared decision-making process. The GDP suggests GnRHa treatment for many children with CPP, although available evidence suggests that some patient subgroups (eg, older girls with slowly progressive CPP) may be less likely to receive a net benefit with this treatment. Rather than always starting GnRHa treatment with a monthly injectable formulation, the GDP suggests that treatment should be initiated with the formulation (such as a longer-acting formulation) that is anticipated to be used long-term. The GDP suggests against routine addition of growth hormone therapy to increase adult height. They also suggest against the routine biochemical testing (eg, LH, sex steroids) to monitor pubertal suppression while receiving GnRHa, instead reserving biochemical testing to confirm clinically suspected treatment failure. Finally, the GDP suggests against routinely continuing GnRHa treatment beyond chronologic age 10.0 to 11.0 years (girls) or 11.0 to 12.0 years (boys) and/or bone age 11.0 to 12.0 years (girls) or 12.0 to 13.0 years (boys). CONCLUSION: These clinical recommendations were developed to address important uncertainties in the diagnosis and treatment of children with CPP. They are based on the best available scientific evidence regarding clinical outcomes judged to be most important to patients and families. The GDP's overarching goal was to suggest diagnostic and therapeutic strategies that will most likely provide net clinical benefits while simultaneously considering important contextual factors such as cost and feasibility. The guideline-development process highlighted important knowledge gaps and the substantial need for additional research.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Latronico AC, Roberts SA, Alonzo M, et al. Central precocious puberty: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2026. PMID: 42287186. doi:10.1210/clinem/dgag168

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。